Researchers estimate that 136.8 million adults in the U.S. are eligible for semaglutide, the generic for Novo Nordisk’s Ozempic, Wegovy and Rybelsus.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
53% of US adults are eligible for Ozempic, Wegovy: Study
